| Primary |
| Acute Myeloid Leukaemia |
15.4% |
| Hodgkin's Disease |
13.3% |
| Acute Lymphocytic Leukaemia |
8.3% |
| Germ Cell Cancer |
6.3% |
| Non-hodgkin's Lymphoma |
5.8% |
| Small Cell Lung Cancer Stage Unspecified |
5.4% |
| Non-small Cell Lung Cancer |
5.0% |
| Chemotherapy |
4.8% |
| Medulloblastoma |
4.5% |
| Diffuse Large B-cell Lymphoma |
4.0% |
| Testis Cancer |
3.5% |
| Prophylaxis |
3.2% |
| Lymphoma |
3.1% |
| Gestational Trophoblastic Tumour |
3.0% |
| Burkitt's Lymphoma |
2.8% |
| Product Used For Unknown Indication |
2.6% |
| Neuroblastoma |
2.3% |
| Non-small Cell Lung Cancer Stage Iii |
2.3% |
| Ewing's Sarcoma |
2.2% |
| Pulmonary Oedema |
2.0% |
|
| Off Label Use |
9.9% |
| Vomiting |
9.5% |
| Thrombocytopenia |
8.5% |
| Sepsis |
8.0% |
| Drug Toxicity |
7.1% |
| Pneumonia |
6.3% |
| Febrile Neutropenia |
5.2% |
| Hearing Impaired |
4.5% |
| Pyrexia |
4.3% |
| Neutropenia |
4.2% |
| Renal Failure Acute |
4.2% |
| Septic Shock |
4.0% |
| White Blood Cell Count Decreased |
3.6% |
| Medication Error |
3.5% |
| Respiratory Failure |
3.5% |
| Pancytopenia |
3.1% |
| Respiratory Disorder |
3.0% |
| Infection |
2.8% |
| Tumour Lysis Syndrome |
2.6% |
| Acute Myeloid Leukaemia |
2.3% |
|
| Secondary |
| Hodgkin's Disease |
12.4% |
| Acute Lymphocytic Leukaemia |
11.0% |
| Acute Myeloid Leukaemia |
8.5% |
| Diffuse Large B-cell Lymphoma |
8.4% |
| Product Used For Unknown Indication |
7.8% |
| Multiple Myeloma |
7.2% |
| Non-hodgkin's Lymphoma |
7.1% |
| Drug Use For Unknown Indication |
5.3% |
| Burkitt's Lymphoma |
5.2% |
| B-cell Lymphoma |
4.0% |
| Lymphoma |
3.8% |
| Prophylaxis |
3.4% |
| Ewing's Sarcoma |
3.0% |
| Neuroblastoma |
2.4% |
| Mantle Cell Lymphoma |
2.2% |
| Medulloblastoma |
2.1% |
| Testis Cancer |
1.8% |
| Small Cell Lung Cancer Stage Unspecified |
1.6% |
| Germ Cell Cancer |
1.4% |
| Rhabdomyosarcoma |
1.4% |
|
| Thrombocytopenia |
9.9% |
| Sepsis |
9.0% |
| Febrile Neutropenia |
8.7% |
| White Blood Cell Count Decreased |
8.6% |
| Vomiting |
8.1% |
| Neutropenia |
7.0% |
| Death |
5.4% |
| Acute Myeloid Leukaemia |
4.2% |
| Pyrexia |
4.2% |
| Myelodysplastic Syndrome |
3.9% |
| Toxicity To Various Agents |
3.8% |
| Pancytopenia |
3.6% |
| Pneumonia |
3.6% |
| Septic Shock |
3.5% |
| Stem Cell Transplant |
3.2% |
| Pneumocystis Jiroveci Pneumonia |
2.9% |
| Respiratory Failure |
2.9% |
| Infection |
2.6% |
| Renal Failure Acute |
2.6% |
| Off Label Use |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
16.7% |
| Prophylaxis |
15.2% |
| Drug Use For Unknown Indication |
7.9% |
| Chemotherapy |
7.0% |
| Diffuse Large B-cell Lymphoma |
4.9% |
| Infection Prophylaxis |
4.7% |
| Bone Marrow Conditioning Regimen |
4.6% |
| Non-hodgkin's Lymphoma |
4.5% |
| Acute Myeloid Leukaemia |
4.1% |
| Prophylaxis Against Graft Versus Host Disease |
4.1% |
| Acute Lymphocytic Leukaemia |
3.3% |
| B-cell Lymphoma |
3.2% |
| Stem Cell Transplant |
3.1% |
| Dehydration |
2.8% |
| Multiple Myeloma |
2.8% |
| Cough |
2.6% |
| Lymphoma |
2.4% |
| Fluid Replacement |
2.2% |
| Medication Dilution |
2.1% |
| Prophylaxis Of Nausea And Vomiting |
1.8% |
|
| Vomiting |
10.5% |
| Thrombocytopenia |
9.4% |
| White Blood Cell Count Decreased |
8.3% |
| Pyrexia |
7.4% |
| Neutropenia |
7.3% |
| Febrile Neutropenia |
6.9% |
| Drug Ineffective |
5.8% |
| Sepsis |
5.8% |
| Respiratory Failure |
4.4% |
| Death |
4.3% |
| Renal Failure Acute |
3.9% |
| Stem Cell Transplant |
3.7% |
| White Blood Cell Count Increased |
3.5% |
| Pancytopenia |
3.2% |
| Weight Decreased |
3.0% |
| Progressive Multifocal Leukoencephalopathy |
2.7% |
| Myelodysplastic Syndrome |
2.5% |
| Nausea |
2.5% |
| Thrombotic Microangiopathy |
2.5% |
| Venoocclusive Liver Disease |
2.5% |
|
| Interacting |
| Ewing's Sarcoma |
29.3% |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive |
11.8% |
| Non-hodgkin's Lymphoma |
8.9% |
| Chemotherapy |
7.9% |
| Product Used For Unknown Indication |
6.6% |
| Acute Myeloid Leukaemia |
5.6% |
| Hiv Infection |
4.3% |
| Hepatosplenic Candidiasis |
3.3% |
| Malignant Hydatidiform Mole |
3.3% |
| General Anaesthesia |
3.0% |
| Hodgkin's Disease |
2.6% |
| Oral Candidiasis |
2.6% |
| Retinoblastoma |
2.6% |
| Gestational Trophoblastic Tumour |
1.6% |
| Bone Sarcoma |
1.3% |
| Diffuse Large B-cell Lymphoma |
1.3% |
| Medulloblastoma |
1.3% |
| Antifungal Prophylaxis |
1.0% |
| Candida Infection |
1.0% |
| Bronchopulmonary Aspergillosis |
0.7% |
|
| Renal Impairment |
19.2% |
| Drug Interaction |
15.4% |
| Neutropenia |
7.7% |
| Paraesthesia |
5.8% |
| Sinoatrial Block |
5.8% |
| Agranulocytosis |
3.8% |
| Diarrhoea |
3.8% |
| Hepatotoxicity |
3.8% |
| International Normalised Ratio Increased |
3.8% |
| Leukopenia |
3.8% |
| Neuropathy Peripheral |
3.8% |
| Ocular Vascular Disorder |
3.8% |
| Reversible Posterior Leukoencephalopathy Syndrome |
3.8% |
| Vaginal Discharge |
3.8% |
| Angioedema |
1.9% |
| Arrhythmia |
1.9% |
| Gamma-glutamyltransferase Increased |
1.9% |
| Neoplasm Progression |
1.9% |
| Neurotoxicity |
1.9% |
| Pancytopenia |
1.9% |
|
